Understand how LH and FSH fit into low testosterone assessment, including primary and secondary patterns, repeat testing and fertility considerations.
A low testosterone result is not an automatic reason to start testosterone replacement therapy (TRT). Adding LH and FSH to a report does not turn it into a treatment decision. These hormones belong in an investigation of how the reproductive hormone system is functioning, not a shortcut from symptoms to a prescription.
The simplified narrative is appealing: symptoms suggest low testosterone, a blood test confirms the suspicion, and treatment follows. What gets lost is the investigation between finding a low result and deciding what that result means.
In a Cleveland Clinic article, andrology specialist Mark Paulos cautions that direct-to-consumer testosterone services can oversimplify assessment when they omit an adequate history and appropriate testing. He also describes growing attention to testosterone as an opportunity for men to raise health concerns with clinicians.
Those positions are compatible. Taking symptoms seriously does not require accepting the first hormonal explanation offered. A careful assessment asks whether testosterone is consistently low and how the wider clinical picture fits.
This article is for informational purposes and is not medical advice. Interpreting hormone results and deciding whether further testing or treatment is appropriate requires a qualified clinician who knows the individual’s health history and circumstances.
LH stands for luteinizing hormone. FSH stands for follicle-stimulating hormone. Both are gonadotropins, hormonal signals that clinicians assess as part of an investigation into reproductive hormone function.
The European Association of Urology (EAU) gives a strong recommendation to measure LH and FSH to help distinguish types of male hypogonadism. Their value comes from their relationship with testosterone and the clinical picture.
At a high level, the investigation asks whether testicular function is impaired or whether the signals stimulating the testes are insufficient. This is why interpreting a total testosterone result in context matters more than treating it as an isolated score.
The EAU describes different patterns depending on whether the problem involves testicular function or inadequate stimulation from the hypothalamus and pituitary. Testosterone provides part of that picture. LH and FSH help clarify the signaling pattern around it.
When testosterone is low, higher LH and FSH can support a primary hypogonadism pattern. Primary hypogonadism involves impaired testicular function.
In this setting, the gonadotropin results help direct attention toward the testes. The finding is not simply that several numbers fall outside their reference ranges. It is that those results form a pattern consistent with impaired testicular function.
Low testosterone alongside low or inappropriately normal gonadotropins can support a secondary hypogonadism pattern. Here, stimulation from the hypothalamus and pituitary is inadequate.
The distinction changes the question being investigated. Rather than focusing only on testicular function, clinicians consider whether the signaling system is providing enough stimulation.
These patterns help classify the problem; they do not identify its exact cause on their own. Recognizing a pattern and explaining why it developed are separate parts of the evaluation.
A laboratory reference range is not the whole interpretation. The EAU specifically describes secondary hypogonadism as involving low or “inappropriately normal” gonadotropins.
That phrase means a result may sit inside the laboratory’s reference range yet still represent an inadequate response in the setting of low testosterone. The number has to be interpreted in relation to the other hormone findings.
The useful question is therefore not only whether LH or FSH is marked as normal. It is whether that result fits with the testosterone level and the broader assessment.
This is a reason to ask for an explanation of the combined results rather than reading each line independently. A normal-range label does not settle the question of adequate hormonal stimulation when testosterone is low.
For late-onset hypogonadism, the EAU recommends combining compatible symptoms or signs with appropriately confirmed low testosterone. Its diagnostic framework includes:
LH and FSH sit within that process. They help distinguish types of hypogonadism rather than replacing the evidence needed to establish testosterone deficiency.
Symptoms also need context. Paulos notes that symptoms alone are not diagnostic and that depression or sleep disorders can produce similar complaints. This is why symptoms need a broader clinical assessment rather than an assumed hormonal explanation.
The practical distinction is between investigating a concern and confirming a diagnosis. Understanding why a low result needs confirmation helps keep those stages separate.
The EAU also describes a compensated or subclinical pattern in which testosterone is normal but LH is higher. It states that the clinical significance of this pattern is unclear.
That uncertainty belongs with this particular finding. It should not be converted into a claim that a man has symptomatic testosterone deficiency merely because LH is flagged.
Normal testosterone with high LH is a different laboratory pattern from low testosterone with high LH. Keeping those patterns separate avoids attaching the same meaning to results that occur in different contexts.
For an individual result, the useful discussion is how the finding fits with symptoms and the rest of the assessment.
A secondary pattern can lead clinicians to consider additional evaluation. The EAU recommends measuring prolactin when secondary hypogonadism occurs with low sexual desire or other suggestive features.
The guideline also recommends pituitary MRI in specified circumstances, including:
These are selected clinical situations, not a recommendation that every man with low testosterone undergo imaging. The decision depends on the findings that accompany the hormone pattern.
There is an important distinction between recognizing a secondary pattern and choosing the next investigation. A clinician uses the broader assessment to decide whether prolactin testing or pituitary evaluation is appropriate. A laboratory flag alone does not make that decision.
Fertility is not a side issue in a testosterone assessment. Paulos emphasizes careful evaluation for primary versus secondary hypogonadism when fertility is relevant because testosterone supplied as treatment suppresses sperm production.
For men who want to preserve fertility, that concern belongs in the conversation before testosterone treatment is considered. A discussion focused only on raising the testosterone number misses this separate consequence.
The practical question is not merely whether treatment might change a blood result. It is how any proposed treatment fits with the man’s reproductive goals and clinical circumstances. Those decisions belong with a qualified clinician rather than a general article or a test-result interpretation made at home.
The evidence supports a clinician-led assessment, not an exercise in matching laboratory flags to diagnoses. LH and FSH are useful because they add structure to the investigation of low testosterone.
Questions worth bringing to a consultation include:
These questions keep attention on the evidence behind the interpretation rather than on the appeal of a quick answer. They also leave room for the broader health assessment that Paulos recommends.
The responsible goal is not to collect more abnormal results or pursue a preferred hormone number. It is to understand the pattern well enough to have an informed discussion about symptoms, possible causes and the next clinical decision.
Deciding what to ask about an LH and FSH pattern is where clinical questions meet the hormone education covered by Testostra. Its evidence-led articles address uncertainty about low testosterone symptoms and their possible causes, giving men a clearer basis for discussion without providing an individual diagnosis or a DIY hormone plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra